SpecialtiesQuestion

Are there any clinical situations in which you consider switching to a subcutaneous formulation of Vedolizumab from IV?

1

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Would you avoid risankizumab in a patient with stricturing Crohn’s complicated by granulomatous bronchiolitis with stenosis who had to stop ustekinumab due to hemoptysis?

In patients treated with infliximab, do rates of immunogenicity vary based on underlying disease (RA, IBD, sarcoidosis, etc) and/or baseline disease activity?

What endoscopic findings on NBI exam help with targeted biopsies for dysplasia surveillance in IBD patients?

What is your approach to terminal ileal structure in the setting of a new diagnosis of Crohn’s disease on index colonoscopy?

Has the PURE study (PMID 40758217) changed how do you prioritize ultraprocessed grain reduction versus low-FODMAP restriction when counseling a patient with quiescent IBD and IBS-like symptoms?

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.